Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 -1.60%74 5-Year Yield-on-Cost % is 5.57 as of Aug. 17, 2026, which is at its 10-year median of 5.57. GuruFocus rates ROCO:6848 with a GF Score™ of 74/100 and a GF Value™ of NT$20.04 (Fairly Valued). The stock has 11 warning signs investors should review. Among 149 Biotechnology companies, RBC Bioscience ranks better than 82.55% on this metric.
RBC Bioscience's yield on cost for the quarter that ended in Dec. 2025 was 5.57.
The historical rank and industry rank for RBC Bioscience's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:6848'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.27 Med: 5.57 Max: 7.62
Current: 5.57
During the past 9 years, RBC Bioscience's highest Yield on Cost was 7.62. The lowest was 1.27. And the median was 5.57.
ROCO:6848's 5-Year Yield-on-Cost % is ranked better than 82.55% of 149
companies
in the Biotechnology industry
Industry Median: 1.64
vs ROCO:6848: 5.57
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
RBC Bioscience 5-Year Yield-on-Cost % Related Terms
ROCO:6848 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, RBC Bioscience's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of RBC Bioscience is calculated as
RBC Bioscience (ROCO:6848) has a 5-Year Yield-on-Cost % of 5.57 as of Aug. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on RBC Bioscience and its competitors. This is near median its historical median of 5.57. Over the past decade, RBC Bioscience's 5-Year Yield-on-Cost % has ranged from 1.27 to 7.62. According to the industry distribution chart, RBC Bioscience ranks #26 out of 149 companies in the Biotechnology industry, placing it in the top 17.4%.
Is RBC Bioscience's 5-Year Yield-on-Cost % too high?
RBC Bioscience's current 5-Year Yield-on-Cost % of 5.57 is near median its 10-year median of 5.57. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 7.62. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.64. RBC Bioscience's value of 5.57 is 239.6% above this industry median. Based on the distribution chart, RBC Bioscience ranks #26 out of 149 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RBC Bioscience has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #26 out of 149 companies for 5-Year Yield-on-Cost %. This places RBC Bioscience in the top 17% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.64. RBC Bioscience's value of 5.57 is 239.6% above this benchmark. Historically, RBC Bioscience's own 5-Year Yield-on-Cost % has ranged from 1.27 to 7.62 over the past decade. While the company's 10-year median is 5.57 vs. the industry median of 1.64, RBC Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RBC Bioscience's current 5-Year Yield-on-Cost % of 5.57 is 239.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on RBC Bioscience and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current 5-Year Yield-on-Cost % is 5.57, which is near median its own 10-year median of 5.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.04, compared to a current price of NT$22.20 — trading 10.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 5.57, which is near median its 10-year median of 5.57 and 239.6% above the Biotechnology industry median of 1.64. RBC Bioscience's overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current 5-Year Yield-on-Cost % is 5.57 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$22.20 is trading 10.8% above its estimated GF Value™ of NT$20.04.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
5-Year Yield-on-Cost %: 5.57 (near median its 10-year median of 5.57)
GF Value™: NT$20.04 vs. price of NT$22.20 (10.8% above fair value)
Industry Position: 239.6% above the Biotechnology median (#26 of 149)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
74GF Score
Get the complete analysis for ROCO:6848
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
